Insmed (INSM) Stock Price & Analysis

INSM$121.44-1.44 -1.17%
BiotechnologyLarge CapGrowth Stock
Compare
Market cap$26.64BEnterprise value$24.48BRevenue (TTM)$1.52BMarket positionTop 25%

Score

62
Neutral
Value
55
Quality
32
Growth
100

AI Analysis

Snapshot

Insmed is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 62/100) in Biotechnology. Under the hood: revenue compounding ~37% annually over recent years. Street targets still imply ~57% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

55
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

32
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Insmed Incorporated (INSM) last printed $121.44. Equity value is $26.64B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$0.00$0.00$9.84M$136.47M$164.41M$188.46M$245.36M$305.21M$363.71M$606.42M

About

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.

Insmed (INSM) Stock Price & Analysis

INSM price $121.44 -1.44 -1.17%

Ticker
INSM
Price
$121.44
Change
-1.44 -1.17%
Market cap
$26.64B
Forward P/E
116.07
Dividend yield
0.00%
Beta
0.81
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
62
Value
55
Quality
32
Growth
100

Stocklytics score rationale: value 55, quality 32, growth 100.

AI Score 35. Insmed Incorporated has a market cap of $24.13 billion but is facing significant challenges with a net profit margin of -39.85% and a price-to-earnings ratio of -39.01. The company is heavily investing in R&D, which is 62.14% of revenue, but continues to report negative net income, indicating ongoing financial struggles despite its innovative pipeline

Insights · Forecast · Financials · Learn

Stocklytics home · Screener